Malaria in the post-genomics era: light at the end of the tunnel or just another train?
Malaria remains the third leading cause of death attributable to an infectious disease worldwide, with an estimated death toll of over 2 million per year, predominately in sub-Saharan Africa. The first serious attempt to eradicate this disease was unsuccessful, and 50 years later in 1998 a second programme coined "roll back malaria" was started. While this programme is at present unlikely to reach its stated aims, the completion of the genome sequencing projects on the human host, the mosquito vector, and the malaria parasite offers new hope. It is probable that the burden of disease caused by the most malignant form of the parasite Plasmodium falciparum can be, if not eliminated, then effectively suppressed within a generation through new and novel treatments aimed at all three arms of malaria control.
Gardiner
D L
DL
Australian Centre for International and Tropical Health and Nutrition, Queensland Institute of Medical Research, Herston, Queensland, Australia. donG@qimr.edu.au
McCarthy
J S
JS
Trenholme
K R
KR
D000818:Animals; D000962:Antimalarials / Q000627:therapeutic use*; D023281:Genomics; D006801:Humans; D008018:Life Cycle Stages; D008288:Malaria / Q000469:parasitology / Q000517:prevention & control*; D017780:Malaria Vaccines; D009032:Mosquito Control / Q000379:methods*; D010963:Plasmodium falciparum / Q000254:growth & development
D000962:Antimalarials; D017780:Malaria Vaccines